Tuesday , August 14 2018
Home / KEEP BUT DO NOT DISPLAY / Facts / PPAR Agonist Safe for Type 2’s

PPAR Agonist Safe for Type 2’s

May 22, 2015

Type 2 diabetes patients showed declines in their A1C, fasting glucose, triglycerides and non-HDL cholesterol levels after nine months of daily treatment of saroglitazar, a dual peroxisome proliferator-activated receptor-agonist. The findings also revealed that the drug did not cause any serious adverse events and was well tolerated by the patients. — “9 Month Safety and Efficacy of Saroglitazar in Diabetes Dyslipidemia.” Presented at: AACE 24th Annual Scientific & Clinical Congress; May 13-17, 2015; Nashville